NABRIVA THERAPEUTICS PLC (NBRV) Fundamental Analysis & Valuation

NASDAQ:NBRV • IE000OZRGNV6

Current stock price

1.42 USD
0 (0%)
At close:
1.3986 USD
-0.02 (-1.51%)
After Hours:

This NBRV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NBRV Profitability Analysis

1.1 Basic Checks

  • NBRV had negative earnings in the past year.
  • In the past year NBRV has reported a negative cash flow from operations.
NBRV Yearly Net Income VS EBIT VS OCF VS FCFNBRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • The profitability ratios for NBRV are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBRV Yearly ROA, ROE, ROICNBRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

1.3 Margins

  • NBRV has a Gross Margin of 18.76%. This is comparable to the rest of the industry: NBRV outperforms 50.24% of its industry peers.
  • NBRV's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NBRV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.92%
GM growth 5YN/A
NBRV Yearly Profit, Operating, Gross MarginsNBRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. NBRV Health Analysis

2.1 Basic Checks

  • NBRV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NBRV has been increased compared to 1 year ago.
  • The debt/assets ratio for NBRV is higher compared to a year ago.
NBRV Yearly Shares OutstandingNBRV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
NBRV Yearly Total Debt VS Total AssetsNBRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -5.39, we must say that NBRV is in the distress zone and has some risk of bankruptcy.
  • NBRV has a worse Altman-Z score (-5.39) than 66.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.39
ROIC/WACCN/A
WACC6.62%
NBRV Yearly LT Debt VS Equity VS FCFNBRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • NBRV has a Current Ratio of 0.85. This is a bad value and indicates that NBRV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.85, NBRV is not doing good in the industry: 90.52% of the companies in the same industry are doing better.
  • NBRV has a Quick Ratio of 0.85. This is a bad value and indicates that NBRV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NBRV's Quick ratio of 0.52 is on the low side compared to the rest of the industry. NBRV is outperformed by 93.84% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.52
NBRV Yearly Current Assets VS Current LiabilitesNBRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NBRV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.40% over the past year.
  • Looking at the last year, NBRV shows a small growth in Revenue. The Revenue has grown by 6.16% in the last year.
  • Measured over the past years, NBRV shows a very strong growth in Revenue. The Revenue has been growing by 47.33% on average per year.
EPS 1Y (TTM)20.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.93%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y57.35%
Revenue growth 5Y47.33%
Sales Q2Q%-5.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.90% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 38.14% on average over the next years. This is a very strong growth
EPS Next Y49.57%
EPS Next 2Y39.49%
EPS Next 3Y30.2%
EPS Next 5Y21.9%
Revenue Next Year89.23%
Revenue Next 2Y66.62%
Revenue Next 3Y52.98%
Revenue Next 5Y38.14%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NBRV Yearly Revenue VS EstimatesNBRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NBRV Yearly EPS VS EstimatesNBRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. NBRV Valuation Analysis

4.1 Price/Earnings Ratio

  • NBRV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NBRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBRV Price Earnings VS Forward Price EarningsNBRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBRV Per share dataNBRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBRV's earnings are expected to grow with 30.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.49%
EPS Next 3Y30.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NBRV Dividend Analysis

5.1 Amount

  • NBRV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NBRV Fundamentals: All Metrics, Ratios and Statistics

NABRIVA THERAPEUTICS PLC

NASDAQ:NBRV (7/31/2023, 8:00:01 PM)

After market: 1.3986 -0.02 (-1.51%)

1.42

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-10
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change7.5%
Ins Owners88.12%
Ins Owner Change0%
Market Cap4.55M
Revenue(TTM)36.51M
Net Income(TTM)-54.07M
Analysts40
Price Target1.02 (-28.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.21%
Min Revenue beat(2)-42.32%
Max Revenue beat(2)-6.1%
Revenue beat(4)1
Avg Revenue beat(4)-14.68%
Min Revenue beat(4)-42.32%
Max Revenue beat(4)5.63%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.63
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-8.32
FCFYN/A
OCF(TTM)-8.26
OCFYN/A
SpS11.4
BVpS-1.36
TBVpS-1.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.76%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.92%
GM growth 5YN/A
F-Score3
Asset Turnover1.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.52
Altman-Z -5.39
F-Score3
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)43.48%
Cap/Depr(5y)38.11%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.93%
EPS Next Y49.57%
EPS Next 2Y39.49%
EPS Next 3Y30.2%
EPS Next 5Y21.9%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y57.35%
Revenue growth 5Y47.33%
Sales Q2Q%-5.36%
Revenue Next Year89.23%
Revenue Next 2Y66.62%
Revenue Next 3Y52.98%
Revenue Next 5Y38.14%
EBIT growth 1Y-3.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.2%
OCF growth 3YN/A
OCF growth 5YN/A

NABRIVA THERAPEUTICS PLC / NBRV Fundamental Analysis FAQ

What is the fundamental rating for NBRV stock?

ChartMill assigns a fundamental rating of 1 / 10 to NBRV.


Can you provide the valuation status for NABRIVA THERAPEUTICS PLC?

ChartMill assigns a valuation rating of 1 / 10 to NABRIVA THERAPEUTICS PLC (NBRV). This can be considered as Overvalued.


How profitable is NABRIVA THERAPEUTICS PLC (NBRV) stock?

NABRIVA THERAPEUTICS PLC (NBRV) has a profitability rating of 0 / 10.